

SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C INFECTION WITH CRUSHED SOFOSBUVIR/VELPATASVIR

Puebla Villaescusa A¹, Gozalo Esteve I¹, Larrea Vargas M¹, Fraile Gallart MJ¹
Hospital San Rafael, Barcelona¹.

BACKGROUND

Sofosbuvir/Velpatasvir (SOF/VEL) is an oral regimen approved for patients with hepatitis C virus (HCV). To date, no data exist on pharmacokinetic impact on the efficacy and security of this regimen when it is crushed and mixed with liquids or food.

PURPOSE

To describe the case of a 65-year-old man patient with HCV infection who successfully achieved a sustained viral response (SVR) when SOF/VEL oral combination was administered crushed and dissolved in 10 ml of water.

MATERIAL AND METHODS

- 65-year-old man patient with HCV infection, genotype 4.
 - Minimal fibrosis (F0-F1)
 - Secondary swallowing problems after a laryngeal neoplasia.
 - Elevated AST (43 U/L), ALT (48 U/L) and GGT (94 U/L) levels at the beginning of the treatment.
 - Normal range for the rest liver profile values.
-
- It was decided the OFF-LABEL treatment with crushed SOF/VEL and dissolved in 10 mL of water for 12 weeks.
 - Serum HCV-RNA was determined at +12 week, +24 week (sustained virologic response, SVR) and a year post-treatment.

RESULTS

- Undetectable serum HCV-RNA at +12 week, +24 week (SVR) and a year post-treatment.
- Normal liver enzymes values were reached at +12 week post-treatment.



< 1 minute to be dissolved in 10 mL of water
Bitter taste according to the patient

CONCLUSION

- SOF/VEL crushed was effective to eradicate Virus C in our patient.
- More studies are needed to determine its bioavailability when it is administrated in a different way from conventional one.
- To develop management guidelines for antiviral drugs with a different way of administration is required.

REFERENCES

- Ficha técnica Eplusa®. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/004210/WC500211151.pdf
- Informe de posicionamiento terapéutico de sofosbuvir/velpatasvir (Eplusa®) en hepatitis C. Disponible en: <https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-sofosbuvir-velpatasvir-Eplusa-hepatitisC.pdf>
- Guías AEEH/SEIMC de manejo de la Hepatitis C. Disponible en: https://seimc.org/contenidos/gruposdeestudio/gehep/dcientificos/documentos/gehep-seimc_AEEH-dc-2018-HepatitisC.pdf
- Sven Stegemann. Drug administration via enteral tubing: an unresolved but increasing challenge. Disponible en: <https://doi.org/10.1517/17425247.2015.976200>

